In the Phase 1, do we know anything about the patients who responded very well (and are still taking P) on a dosing schedule of less than 30 mg/daily? I assume they were refractory to other TKIs (or T315i patients)....were any of these people NOT on any other TKI for an extended period of time?
Market Data 
Markets 
AI
